⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL13738816 | 0.79 | TYR (0.33) | — | |
| SCHEMBL7369233 | 0.76 | — | — | |
| SCHEMBL1036921 | 0.75 | DPP4 (0.50) | — | |
| SCHEMBL3754568 | 0.75 | DPP4 (0.50) | — | |
| SCHEMBL255230 | 0.75 | DPP4 (0.50) | — | |
| SCHEMBL4958723 | 0.74 | DPP4 (0.30) | — | |
| Hydrochloric Acid SCHEMBL3388587 | 0.73 | DRD1 (0.32) | — | |
| Hydrochloric Acid SCHEMBL2035158 | 0.73 | DRD1 (0.32) | — | |
| Hydrochloric Acid SCHEMBL20900097 | 0.73 | DPP4 (0.48) | — | |
| Hydrochloric Acid SCHEMBL28664928 | 0.73 | DPP4 (0.48) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9682955-B2 | Quinazoline derivatives useful as CB-1 inverse agonists | JANSSEN PHARMACEUTICA NV (BE) | 2017-06-20 | — | — | US | claimed |
| WO-2016040081-A1 | QUINAZOLINE DERIVATIVES USEFUL AS CB-1 INVERSE AGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2016-03-17 | — | — | WO | claimed |
| US-20160068512-A1 | Quinazoline Derivatives Useful as CB-1 Inverse Agonists | JANSSEN PHARMACEUTICA NV (BE) | 2016-03-10 | — | — | US | claimed |
| EP-1131290-B1 | PIPERIDINE CCR-3 RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2008-02-20 | — | — | EP | claimed |
| US-6342509-B1 | ANTIASTHMATICS, ANTIHISTAMINES OR BRONCHODIALATORS | SYNTEX (U.S.A.) LLC | 2002-01-29 | — | — | US | claimed |
| EP-1131290-A1 | PIPERIDINE CCR-3 RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2001-09-12 | — | — | EP | claimed |
| WO-2000031033-A1 | PIPERIDINE CCR-3 RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2000-06-02 | — | — | WO | claimed |
| US-9682955-B2 | Quinazoline derivatives useful as CB-1 inverse agonists | JANSSEN PHARMACEUTICA NV (BE) | 2017-06-20 | — | — | US | disclosed |
| WO-2016040081-A1 | QUINAZOLINE DERIVATIVES USEFUL AS CB-1 INVERSE AGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2016-03-17 | — | — | WO | disclosed |
| US-20160068512-A1 | Quinazoline Derivatives Useful as CB-1 Inverse Agonists | JANSSEN PHARMACEUTICA NV (BE) | 2016-03-10 | — | — | US | disclosed |
| EP-1131290-B1 | PIPERIDINE CCR-3 RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2008-02-20 | — | — | EP | disclosed |
| EP-1131290-A1 | PIPERIDINE CCR-3 RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2001-09-12 | — | — | EP | disclosed |
| WO-2000031033-A1 | PIPERIDINE CCR-3 RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2000-06-02 | — | — | WO | disclosed |